Fol. Biol. 2009, 55, 177-182
https://doi.org/10.14712/fb2009055050177
Metastases Development Following Local Tumour Treatment
References
1. , R., Mileva, M., Zvetkova, E (2001) Nitric oxide and cancer. Exp. Pathol Parasitol. 4, 13-18.
2. Baum, M., Badwe, R. A. Does surgery influence the natural history of breast cancer? In: Wise, H., Johnson, H. J. eds. Breast Cancer: Controversies in Management. Futura Publishing Co., Armonk, NY, 1994, 61-69.
3. , M., Demicheli, R., Hrushesky, W., Retsky, M. (2005) Does surgery unfavourably perturb the “natural history” of early breast cancer by accelerating the appearance of distant metastases. Eur. J. Cancer 41, 508-515.
<https://doi.org/10.1016/j.ejca.2004.09.031>
4. , M., Colombo, B. M (2005) Anti-angiogenic strategies for cancer therapy. Int. J. Oncol. 27, 563-571.
5. , J., Šimova, J. (2005) Minimal residual disease as target for immunotherapy and gene therapy of cancer (Review). Oncol. Rep. 14, 1377-1380.
6. , M. M., Mathur, P., Carnochan, P., Saini, S., AllenMerch, T. G (2002) Effects of manipulation of primary tumor vascularity on metastases in an adenocarcinoma model. Br. J. Cancer 86, 123-129.
<https://doi.org/10.1038/sj.bjc.6600020>
7. , R. (2001) Tumour dormancy: findings and hypothesis from clinical research on breast cancer. Semin. Cancer Biol. 11, 297-305.
<https://doi.org/10.1006/scbi.2001.0385>
8. , R., Valagussa, P., Bonadona, G. (2001) Does surgery modify growth kinetics of breast cancer metastases? Br. J. Cancer 85, 490-491.
<https://doi.org/10.1054/bjoc.2001.1969>
9. , K. E., Eichten, A., Coussens, L. M (2006) Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 6, 24-37.
<https://doi.org/10.1038/nrc1782>
10. , M., Werb, Z. (2002) New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 163-176.
<https://doi.org/10.1038/nrc745>
11. , I. J. (1990) Critical factors in the biology of human cancer metastases: Twenty-eighth GHA Clowes Memorial Award Lecture. Cancer Res. 50, 6030-6038.
12. , I. J. (1994) Experimental orthotopic models of organspecific metastasis by human neoplasms. Adv. Mol. Cell Biol. 9, 191-215.
<https://doi.org/10.1016/S1569-2558(08)60385-9>
13. , I. J. (2002) Critical determinants of metastases. Sem. Cancer Biol. 12, 89-96.
<https://doi.org/10.1006/scbi.2001.0416>
14. , J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27-31.
<https://doi.org/10.1038/nm0195-27>
15. , D. J., Polverini, P. J., Rastinejad, F., LeBeau, M. M., Lomons, R. S., Frazier, W. A., Bouck, N. P. (1990) A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. USA 87, 6624-6628.
<https://doi.org/10.1073/pnas.87.17.6624>
16. , M., Singh, R. K., Price, J. E., Fan, D., Fidler, I. J. (1995) Accelerated growth of human colon cancer cells in nude mice undergoing liver regeneration. Invas. Met. 14, 362-371.
17. , G. H., Miller, F. R. (1998) The cellular basis of tumor progression. Int. Rev. Cytol. 177, 1-56.
18. , L., O’Reilly, M. S., Folkman, J. (1995) Dormancy in micrometastases: balanced proliferation and apoptosis in the presence of angiogenic suppression. Nat. Med. 1, 149-153.
<https://doi.org/10.1038/nm0295-149>
19. , M., Bieblova, J., Bubenik, J., Reiniš M. (2008) IL12 immunotherapy of minimal residual disease in murine model of HPV16-associated tumours: Induction of immune responses, cytokine production and kinetics of immune cell subsets. Int. J. Oncol. 32, 499-507.
20. , M., Suit, H. D. (1974) In vitro activity of lymphocytes and serum of C3hF/Bu mice during the growth of methylcholanthrene-induced tumor and its regression following local irradiation. Cancer Res. 34, 672-678.
21. Khokha, R, Voura, E., Hill, R. P. (2005) Tumor progression and metastasis: Cellular, molecular and microenvironmental factors. In: Tannock, I. F., Hill, R. P., Bristow, R. G., Harrington, L. eds. The Basic Science of Oncology, fourth edition, New York, Chicago, San Francisco, Lisbon, London, Madrid, Mexico City, Milan, New Delhi, San Juan, Seoul, Sydney, Toronto. McGraw-Hill Medical Publishing Division, 205-230.
22. , R., Indrova, M., Šimova, J., Jandlova, T., Bieblova, J., Jinoch, P., Bubenik, J., Vonka, V (2004) Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumors: cytokine and gene therapy with IL-2 and GM-CSF. Int. J. Oncol. 24, 161-168.
23. , S., Keilholz, U., Rossi, C. R., Nitti, D. (2006) Circulating tumor cells: the “leukemic phase” of solid cancers. Trends Mol. Med. 12, 130-139.
<https://doi.org/10.1016/j.molmed.2006.01.006>
24. , F. W., Wang, H. H., Lafrenie, R. M., Scherbarth, S., Nance, D. M (2000) Interaction between cancer cells and the endothelium in metastasis. J. Pathol. 190, 310-329.
<https://doi.org/10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P>
25. , E. K., Mathiesen, B., Kindem, K., Galappathi, K. (2006) Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic mice. Cancer Res. 66, 6699-6707.
<https://doi.org/10.1158/0008-5472.CAN-06-0983>
26. , C. D., Capone, G. T., Scher, C. D., Aqntoniades, H. N., Van Wyk, J. J., Pledger, W. J. (1979) Dual control of cell growth by somatomedins and platelet-derived growth factor. Proc. Natl. Acad. Sci. USA 76, 1279-1283.
<https://doi.org/10.1073/pnas.76.3.1279>
27. , P. Y., Guo, L., Gao, C. J., Mi, Z. Y., Guo, H. T., Kuo, P. C. (2006) Osteopontin inhibits macrophage nitric oxide synthesis to enhance tumor proliferation. Surgery 140, 132-140.
<https://doi.org/10.1016/j.surg.2006.02.005>
